Fluoroquinolone resistance and Mycobacterium tuberculosis: CAP guidelines play an important role

International Journal of Tuberculosis and Lung Disease

Volumn 18, Issue 5, 2014, Pages 628-629

  Goyet, Sophie ^a   Vlieghe, Erika ^b   Lim, Kruy ^c   Van Griensven, Johan ^b,c   Borand, Laurence ^a   Thong, Phe ^c   Rammaert, Blandine ^a   Marcy, Olivier ^a   Tarantola, Arnaud ^a  

^a INSTITUT PASTEUR DU CAMBODGE   (Cambodia)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^c Sihanouk Hospital Center of HOPE   (Cambodia)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BETA LACTAMASE INHIBITOR; MACROLIDE; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; CAMBODIA; COMMUNITY ACQUIRED PNEUMONIA; DRUG USE; INAPPROPRIATE PRESCRIBING; INFECTION RISK; LETTER; LUNG TUBERCULOSIS; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; TUBERCULOSIS; DRUG EFFECTS; HUMAN; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTIBIOTICS, ANTITUBERCULAR; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84899575449     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.13.0922     Document Type: Letter

References (12)

1. Yew W-W, Lange C. Fluoroquinolone resistance in Mycobacterium tuberculosis. What have we learnt? [Editorial]. Int J Tuberc Lung Dis 2014; 18: 1-2.
2. Rammaert B, Goyet S, Beauté J, et al. Klebsiella pneumoniae related community-acquired acute lower respiratory infections in Cambodia: clinical characteristics and treatment. BMC Infect Dis 2012; 12: 3.
3. Chen T-C, Lu P-L, Lin C-Y, Lin W-R, Chen Y-H. Fluoroquinolones are associated with delayed treatment and resistance in tuberculosis: a systematic review and meta-analysis. Int J Infect Dis 2011; 15: e211-216.
4. Jeon K, Koh W-J. Predictors of developing acute respiratory distress syndrome in patients with miliary tuberculosis. Int J Tuberc Lung Dis 2011; 15: 995.
5. Rammaert B, Goyet S, Tarantola A, et al. Acute lower respiratory infections on lung sequelae in Cambodia, a neglected disease in highly tuberculosis-endemic country. Respir Med 2013; 107: 1625-1632.
6. Low D E. Fluoroquinolones for treatment of community-acquired pneumonia and tuberculosis: putting the risk of resistance into perspective. Clin Infect Dis 2009; 48: 1361-1363.
7. World Health Organization. Global tuberculosis report 2013. WHO/HTM/TB/2013.11. Geneva, Switzerland: WHO, 2013.
8. World Health Organization. Cambodia turns a TB health crisis into an opportunity Geneva, Switzerland: WHO, 2012. http://www.who.int/features/2012/tb- cambodia/en/ Accessed January 2014.
9. Khann S, Mao E T, Rajendra Y P, Satyanarayana S, Nagaraja S B, Kumar A M V. Linkage of presumptive multidrug resistant tuberculosis (MDR-TB) patients to diagnostic and treatment services in Cambodia. PLoS One 2013; 8(4).
10. Surcouf C, Heng S, Pierre-Audigier C, et al. Molecular detection of fluoroquinolone-resistance in multi-drug resistant tuberculosis in Cambodia suggests low association with XDR phenotypes. BMC Infect Dis 2011; 11: 255.
11. Chareonkul C, Khun V L, Boonshuyar C. Rational drug use in Cambodia: study of three pilot health centers in Kampong Thom Province. Southeast Asian J Trop Med Public Health 2002; 33: 418-424.
12. Migliori G B, Langendam M W, D'Ambrosio L, et al. Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones. Eur Respir J 2012; 40: 814-822.